The Increasingly Human and Profitable Monoclonal Antibody Market

The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Trends in biotechnology (Regular ed.) 2019-01, Vol.37 (1), p.9-16
Hauptverfasser:	Grilo, António L., Mantalaris, A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Asthma biosimilars Breast cancer Colorectal cancer Diabetes Diabetic retinopathy Edema Emerging markets FDA approval Inflammatory bowel disease Lung cancer Lymphoma Manufacturing market analysis Markets Melanoma Metastasis Monoclonal antibodies monoclonal antibody Multiple myeloma Multiple sclerosis Neuroblastoma Psoriasis Regulatory approval Rheumatoid arthritis Therapeutic applications
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure of mAbs, dominant companies, manufacturing locations, and emerging markets.
ISSN:	0167-7799 1879-3096
DOI:	10.1016/j.tibtech.2018.05.014